Immune checkpoint therapy in liver cancer
Abstract Immune checkpoints include stimulatory and inhibitory checkpoint molecules. In recent years, inhibitory checkpoints, including cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand 1 (PD-L1), have been identified to su...
Main Authors: | Feng Xu, Tianqiang Jin, Yuwen Zhu, Chaoliu Dai |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-018-0777-4 |
Similar Items
-
Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
by: Ran Qin, et al.
Published: (2023-12-01) -
Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
by: Jin Zhang, et al.
Published: (2023-03-01) -
Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma
by: Joanna Jiang, et al.
Published: (2022-12-01) -
Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake
by: Yannick S. Rakké, et al.
Published: (2024-02-01) -
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
by: Nikolaos Machairas, et al.
Published: (2022-04-01)